Report Highlights
- The global pharmaceutical contract manufacturing and contract research organizations revenue reached at $196.5 billion in 2010, it will further grow to $217.9 billion in 2011 and is projected to reach at $360.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 10.6%.
- North American markets’ revenue for bulk drugs in contract manufacturing in 2009 was about $8.8 billion and increased to about $9.7 billion in 2010. It is projected to reach $16.6 billion by 2016, for a 5-year CAGR of 9.4%.
- The total market for solid dosage form contract manufacturing in 2010 was valued at about $9.1 billion. This is expected to reach $10 billion by 2011 and forecasted to cross $16.1 billion by the end of 2016 at a CAGR of 10% for the five year period.
INTRODUCTION
STUDY OBJECTIVE
The objective of BCC Research in conducting this study is to provide an overview of the current situation and future capabilities of the global pharmaceutical contract manufacturing, research, and packaging markets. The study provides a global as well as a regionally specific market overview. The report emphasizes the current and future outlook of the pharmaceutical contract manufacturing market, with a comprehensive analysis of the overall pharmaceutical and biotechnology outsourcing industry.
The current report discusses and outlines the current capabilities as well as the needs of the pharmaceutical contract manufacturing, research, and packaging markets. In addition, it discusses company and market strategies to further enhance the market. The report includes the different types of contract manufacturing and, more specifically, the services offered by global contract manufacturers, researchers, and packagers. The report also discusses the methods best used to identify an effective contract manufacturer as well as the advantages of contract manufacturing and outsourcing. The report highlights the need for project management, provides market forecasts for different aspects of contract manufacturing specific to each region, and examines the role of market leaders in the industry. Regulatory requirements and new developments in the market are also discussed in the report.
The report encompasses the revenues gained from contract manufacturing in each specific market and in each specific region. Sales analysis was performed on specific categories of drugs and dosage forms including API/bulk drugs and solid, liquid, and semisolid dosage forms. Sales analyses were also performed on revenues gained from contract packaging and contract research. The sales figures discussed are for the examined period of 2009 to 2011. Sales figures were also forecast for the following 5-year period from 2011 through 2016.
Over-the-counter (OTC) drugs, nutritional drugs, and drug delivery products are discussed in a separate section of this report.
REASONS FOR DOING THIS STUDY
The majority of pharmaceutical companies are now using contract manufacturing, research, and packaging services. To save costs and product development time while simultaneously being effective, efficient, and productive, pharmaceutical companies are relying on contract manufacturers to fulfill many basic as well as specialized competencies. This study discusses the different types of contracting companies, their roles, and the share of the market they claim. New developments and new technologies warrant the issuing of this report, which is an important resource for anyone analyzing the discussed markets.
Trends in outsourcing and new emerging markets for outsourcing are providing a new look to the market and greater options to pharmaceutical companies. The industry is seeing an increase in outsourcing as contract manufacturers, researchers, and packagers provide cheaper options as well as region-specific suppliers. The new state-of-the-art packaging facilities as well as expensive research facilities and capabilities of research organizations are enhancing the overall growth of the contract manufacturing industry. Contract manufacturers are providing pharmaceutical companies with expertise in all forms that the companies do not have available in-house.
INTENDED AUDIENCE
This study examines the areas of market growth in pharmaceuticals contract manufacturing, research, and packaging from the point of view of manufacturers and users. Strategic decision makers at biochemical and biotechnology companies, physicians, pharmaceuticals and biopharmaceuticals companies, and related research companies will find value in this study.
SCOPE OF THE STUDY
The scope of this study encompasses the contract manufacturing, research, and packaging markets. BCC analyzes each market and its applications for contract manufacturing by its need for outsourcing, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical, chemical, pharmaceutical, and contracting experts. Market sizing estimates and projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of pharmaceuticals through contract manufacturing and research. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, and consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.
ABOUT THE AUTHOR
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents of Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs, Implants, and Devices; Imaging Reagents; Regulatory Industry; Dynamic Sera, Media, and Reagents Used in Biotechnology; Contract Pharmaceutical Manufacturing, Research, and Packaging; Chiral Technology: Global Markets; Autacoids, and Related Drugs; Contraceptives; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs, and Devices; Cancer Therapies: Technologies and Global Market; and Medical Imaging Reagents and Analysis Equipment.
The lead consultant for this project was Ms. Taruna Chhabra, who holds a bachelor’s degree in biology and is a member of the National Honor Society for Biological Sciences.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers.
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Related Reports
The Clinical Trials Business
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period. Clinical trial spending in 2010 is an estimated $25 billion and is expected to reach $28.5 billion by 2014.
Recent Reports
Global Oncology Pharmaceuticals Market
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Excipients in Pharmaceuticals: Global Markets to 2029
The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.
Antibody-Drug Conjugates: Technologies and Global Markets
The global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to reach $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.
Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging
The global market for contract pharmaceutical manufacturing, research and packaging is estimated to increase from $212.2 billion in 2023 to reach $310.2 billion by 2029, at a compound annual growth rate (CAGR) of 6.7% from 2024 through 2029.
Global Markets for Drug-Device Combinations
The global market for drug-device combinations is expected to grow from $129.4 billion in 2024 and is projected to reach $199.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.1% during the forecast period of 2024 to 2029.
Top Trending Reports
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
Artificial Intelligence (AI) in Life Sciences Market
The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.
Drug Discovery Technologies
The global market for drug discovery technologies is expected to grow from $111.9 billion in 2024 and is projected to reach $197.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.0% during the forecast period of 2024 to 2029.
Synthetic Biology: Global Markets
The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.
Electric Vehicles and Fuel Cell Vehicles: Global Markets
The global market for electric vehicles and fuel cell vehicles was valued at $655.9 billion in 2023. The market is expected to grow from $758.0 billion in 2024 to $1.8 trillion by 2029, at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More